



INFORMAZIONI PERSONALI

GIULIA D'ARCANGELO

Email aziendale giulia.darcangelo@policlinico.mi.it

Posta Elettronica Certi giulia.darcangelo@omceoromapec.it

Sesso Femmina Data di Nascita 30/09/1987 Nazione ITALIA

POSIZIONE RICOPERTA DIRIGENTE MEDICO

ESPERIENZA PROFESSIONALE

Da Maggio 2023 a Dicembre 2024 DIRIGENTE MEDICO

POLICLINICO UMBERTO I

DIRIGENTE MEDICO PEDIATRIA

Attività o Settore Sanità e assistenza sociale

ISTRUZIONE E FORMAZIONE

Dal 2019 a Febbraio 2024 DOTTORATO IN TECNOLOGIE BIOMEDICHE INNOVATIVE IN MEDICINA CLINICA

SAPIENZA UNIVERSITA' DI ROMA

Da Dicembre 2014 a Dicembre 2019 SPECIALIZZAZIONE IN PEDIATRIA

SAPIENZA UNIVERSITA' DI ROMA

Da Gennaio 2012 a Gennaio 2013 MASTER DI II LIVELLO

SAPIENZA UNIVERSITA' DI ROMA

GASTROENTEROLOGIA PEDIATRICA

Da Ottobre 2005 a Ottobre 2011 LAUREA IN MEDICINA E CHIRURGIA

SAPIENZA UNIVERSITA' DI ROMA

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C2	C2	C2	C2	C2
Francese	C2	C2	C2	C1	C1

Livelli: A 1/2 Livello Base - B 1/2 Livello Intermedio - C 1/2 Livello Avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze organizzative e gestionali Lavoro di squadra
Project management e project coordinationCompetenze professionali Pediatria generale
Gastroenterologia pediatrica
Malattie Infiammatorie Croniche Intestinali Pediatriche
Ottima conoscenza del pacchetto Office



Competenze informatiche

Ottima conoscenza del software di statistica Graphpad
B

Patente di guida

ALLEGATI

CV sep 2025_D'arcangelo (1)_compressed.pdf

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 'Codice in materia di protezione dei dati personali'.

CURRICULUM VITAE



PERSONAL INFORMATION

Name **GIULIA D'ARCANGELO**
Date of birth **SEPTEMBER 30, 1987**
Telephone **(+39)3249972595**
Email **Giulia.darcangelo@uniroma1.it**

PROFILE Pediatrician with strong scientific background in Pediatrics and specifically in Pediatric Gastroenterology with a focus on Inflammatory Bowel Diseases, and Pediatric Immune-mediated diseases.

WORK EXPERIENCE

Current Position Pediatric Gastroenterologist at Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Sep 2022- May 2025 - Pediatric Gastroenterologist at Umberto I Hospital
- CoPi of the project "New Non-Invasive Techniques In The Management Of Pediatric Inflammatory Bowel Diseases: Improving Quality Of Care And Reducing National Health System Costs" at the Pediatric Gastroenterology Unit, Umberto I Hospital, Sapienza University of Rome
- Co-Pi of the project "Role of Diet in the pathophysiology of Inflammatory Bowel Disease and related Rheumatic Inflammatory conditions. Dissecting mechanism of actions of nutritional treatments" at the Pediatric Gastroenterology Unit, Umberto I Hospital, Sapienza University of Rome

Dec 2019-Sep 2021 Editor of the column "Recent advances in basic science" of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP) journal

Dec 2019-Aug 2021 Project Coordinator at Pediatric Gastroenterology Unit, Sapienza University of Rome

Dec 2019-Aug 2021 Pediatric Gastroenterologist at Pediatric Gastroenterology Unit, Umberto I Hospital, Sapienza University of Rome

EDUCATION

Achived titles M.D., magna cum laude, Sapienza Medical School, University of Rome, Oct 2011

Master course in Pediatric gastroenterology, Endoscopy and Hepatology, magna cum laude, Sapienza University of Rome, Jan 2013

Board of Pediatrics, magna cum laude, Sapienza Medical School, University of Rome, Dec 2019

Master Degree in Pediatric gastroenterology, Hepatology and Nutrition, Sapienza University of Rome, Dec 2020

PhD in Biotechnology in Clinical Medicine, Sapienza University of Rome Project title: Towards the path of precision medicine: new non-invasive markers for inflammatory bowel disease. Prokineticin 2, lipocalin-2, brain-derived neurotrophic factor and nerve growth factor: a pilot study

Disease course and outcome of medical therapy in pediatric stricturing Crohn's disease. Aloï M, Viola F, D'Arcangelo G, Di Nardo G, Civitelli F, Casciani E, Oliva S, Nuti F, Dilillo A, Cucchiara S. *Dig Liver Dis*. 2013 Jun;45(6):464-8

Presenting features and disease course of pediatric onset ulcerative colitis. Aloï M, D'Arcangelo G, Pofi F, Vassallo F, Rizzo V, Nuti F, Di Nardo G, Pierdomenico M, Viola F, Cucchiara S. *J Crohns Colitis*. 2013 Dec;7(11):e509-15. doi: 10.1016/j.crohns.2013.03.007. Epub 2013 Apr 11.

Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy. Aloï M, D'Arcangelo G, Capponi M, Nuti F, Vassallo F, Civitelli F, Oliva S, Pagliaro G, Cucchiara S. *Dig Liver Dis*. 2015 Jun;47(6):455-9. doi: 10.1016/j.dld.2015.01.156. Epub 2015 Feb 4.

Aortic Intima-Media Thickness as an Early Marker of Atherosclerosis in Children With Inflammatory Bowel Disease. Aloï M, Tromba L, Rizzo V, D'Arcangelo G, Dilillo A, Blasi S, Civitelli F, Kiltzanidi D, Redler A, Viola F. *J Pediatr Gastroenterol Nutr*. 2015 Jul;61(1):41-6. doi: 10.1097/MPG.0000000000000771.

Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis.. Aloï M, D'Arcangelo G, Bramuzzo M, Gasparetto M, Martinelli M, Alvisi P, Illiceto MT, Valenti S, Distanti M, Pellegrino S, Gatti S, Arrigo S, Civitelli F, Martelossi S; SIGENP IBD Working Group. *Inflamm Bowel Dis*. 2016 Jul;22(7):1647-54. doi: 10.1097/MIB.0000000000000828

Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management. D'Arcangelo G, Aloï M. *Paediatr Drugs*. 2017 Apr;19(2):113-120. doi: 10.1007/s40272-017-0213-9. Review.

Efficacy and safety of adalimumab after infliximab failure in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD Registry Aloï M, Bramuzzo M, Arrigo S, Romano C, D'Arcangelo G, Lacorte D, Gatti S, Illiceto MT, Zucconi F, Dilillo D, Zuin G, Knafelz D, Ravelli A, Cucchiara S and Alvisi P; on behalf of the SIGENP IBD Working Group. *J Pediatr Gastroenterol Nutr*. 2018 Jun;66(6):920-925. doi: 10.1097/MPG.0000000000001883.

Predictors of Long-Term Clinical and Endoscopic Remission in Children With Crohn's Disease Treated With Infliximab. D'Arcangelo G, Oliva S, Dilillo A, Viola F, Civitelli F, Isoldi S, Cucchiara S, Aloï M. *J Pediatr Gastroenterol Nutr*. 2019 Jan 8. doi: 10.1097/MPG.0000000000002262

Mucosal healing in Crohn's disease: new insights. Cucchiara S, D'Arcangelo G, Isoldi S, Aloï M, Stronati L. *Expert Rev Gastroenterol Hepatol*. 2020 May;14(5):335-345. doi: 10.1080/17474124.2020.1759416. Epub 2020 May 13.

Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? D'Arcangelo G, Aloï M. *Paediatr Drugs*. 2020 Jun 23. doi: 10.1007/s40272-020-00406-2. Online ahead of print.

Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. *Dig Liver Dis*. 2021 Feb;53(2):183-189. doi: 10.1016/j.dld.2020.10.024. Epub 2020 Oct 22

Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group. Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Celano R, Civitelli F, D'Arcangelo G,

Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Panceri R, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. *Dig Liver Dis.* 2020 Dec 26:S1590-8658(20)31090-2. doi: 10.1016/j.dld.2020.12.011. Online ahead of print

Safety of Biological Therapy in Children With Inflammatory Bowel Disease. D'Arcangelo G, Distante M, Raso T, Rossetti D, Catassi G, Aloï M. *J Pediatr Gastroenterol Nutr.* 2021 Jan 6; Publish Ahead of Print. doi: 10.1097/MPG.0000000000003044. Online ahead of print.

Quality of life in long term survivors of pediatric intestinal transplantation compared with liver transplantation and home parenteral nutrition: A prospective single-center pilot study. Proli F, Metou-Lopes A, Ayachi A, Rossi M, D'Arcangelo G, Faragalli A, Lambe C, Talbotec C, Goulet O, Chardot C, Lacaille F. *Pediatr Transplant.* 2021 Feb 16:e13982. doi: 10.1111/petr.13982. Online ahead of print.

Is Fecal Calprotectin a Useful Marker for Small Bowel Crohn's Disease? D'Arcangelo G, Imondi C, Terrin G, Catassi G, Aloï M. *J Pediatr Gastroenterol Nutr.* 2021 Aug 1;73(2):242-246. doi: 10.1097/MPG.0000000000003151.

Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study. D'Arcangelo G, Abi Nader E, Charbit-Henrion F, Talbotec C, Goulet O, Ruemmele FM, Pigneur B. *J Pediatr Gastroenterol Nutr.* 2022 Jan 1;74(1):79-84. doi: 10.1097/MPG.0000000000003301

Factors associated with quality of life in Italian children and adolescents with IBD. Gatti S, Del Baldo G, Catassi G, Faragalli A, Aloï M, Bramuzzo M, D'Arcangelo G, Felici E, Fuoti M, Lega S, Panceri R, Pastore M, Penagini F, Gesuita R, Catassi C. *Sci Rep.* 2021 Sep 10;11(1):18076. doi: 10.1038/s41598-021-97661-1

Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease. Aloï M, D'Arcangelo G, Rossetti D, Bucherini S, Felici E, Romano C, Martinelli M, Dipasquale V, Lionetti P, Oliva S. *Inflamm Bowel Dis.* 2022 Aug 9; izac172. doi: 10.1093/ibd/izac172. Epub ahead of print. PMID: 35942651

Natural history of anemia and efficacy and safety of oral iron therapy in children newly diagnosed with inflammatory bowel disease. D'Arcangelo G, Distante M, Veraldi S, Tarani F, Musto F, Aloï M. *J Pediatr Gastroenterol Nutr.* 2023 Mar 17. doi: 10.1097/MPG.0000000000003764. Online ahead of print

Disease course of ulcerative proctitis in children: A population-based study on behalf of the SIGENP IBD Group. Martinelli M, Fedele F, Romano C, Aloï M, Lionetti P, Alvisi P, Arrigo S, Bosa L, Bramuzzo M, D'Arcangelo G, Dipasquale V, Felici E, Fuoti M, Gatti S, Graziano F, Illiceto MT, Labriola F, Norsa L, Pastore M, Scarallo L, Strisciuglio C, Zuin G, Miele E, Staiano A. *Dig Liver Dis.* 2023 Jul 20:S1590-8658(23)00760-0. doi: 10.1016/j.dld.2023.07.008. Online ahead of print.

A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn's Disease Improves Outcomes at 2 Years. D'Arcangelo G, Russo G, Aloï M, Ruggiero C, Maccioni F, Hassan C, Papoff P, Cohen SA, Oliva S. *Inflamm Bowel Dis.* 2023 Aug 21; izad173. doi: 10.1093/ibd/izad173. Online ahead of print.

Histologic findings at diagnosis as predictive markers of clinical outcome in pediatric ulcerative colitis. Catassi G, Tittarelli S, Veraldi S, Giordano C, Distante M, D'Arcangelo G, Oliva S, Arienzo F, Aloï M. *Dig Liver Dis.* 2024 Jan;56(1):106-111.

Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN. Catassi G, D'Arcangelo G, Norsa L, Bramuzzo M, Hojsak I,

Kolho KL, Romano C, Gasparetto M, Di Giorgio A, Hussey S, Yerushalmy-Feler A, Turner D, Matar M, Weiss B, Karoliny A, Alvisi P, Tzivnikos C, Aloï M. *Inflamm Bowel Dis*. 2023 Sep 28;izad218.

Diagnostic accuracy of multimodal noninvasive follow-up for pediatric ulcerative colitis: A single-center prospective study. Spyropoulou V, Russo G, Rossi ED, Ruggiero C, Volpe D, D'Arcangelo G, Papoff P, Civitelli F, Aloï M, Oliva S. *J Pediatr Gastroenterol Nutr*. 2024 Feb;78(2):280-288.

Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition. Weintraub Y, Collen LV, Hussey S, Mitrova K, Machta JS, Kang B, Granot M, D'Arcangelo G, Spencer EA, Kolho KL, Yeh PJ, Sladek M, Scarallo L, Palomino L, Afzal NA, de Laffolie J, Miele E, Bramuzzo M, Olén O, Russell RK, Rohani P, Tzivnikos C, Urlep D, van Rheeën PF, de Ridder L, Yogev D, Schneider AM, Cohen S, Garcia-Romero R, Dipasquale V, Uhlig HH, Shouval DS. *Inflamm Bowel Dis*. 2025 Jan 15;izae302. doi: 10.1093/ibd/izae302. Online ahead of print. PMID: 39813158

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study. Cohen S, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Uhlig HH, Tzivnikos C, Henderson P, Wlazlo M, Hackl L, Shouval DS, Bramuzzo M, Urlep D, Olbjørn C, D'Arcangelo G, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungoe C, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Rimón RM, Granot M, Scarallo L, Trindade E, Rodríguez-Belvis MV, Turner D, Yerushalmy-Feler A. *Aliment Pharmacol Ther*. 2025 Apr;61(8):1372-1380. doi: 10.1111/apt.70016. Epub 2025 Feb 8. PMID: 39921898

Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study. Yerushalmy-Feler A, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Uhlig HH, Tzivnikos C, Ancona S, Wlazlo M, Hackl L, Shouval DS, Bramuzzo M, Urlep D, Olbjørn C, D'Arcangelo G, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungoe C, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Magen Rimón R, Granot M, Scarallo L, Trindade E, Velasco Rodríguez-Belvis M, Turner D, Cohen S. *J Crohns Colitis*. 2025 May 8;19(5):jjae182. doi: 10.1093/ecco-jcc/jjae182. PMID: 39605286.

Prevalence and trend of anemia in children with inflammatory bowel disease: A national register-based cohort study. D'Arcangelo G, Brecciaroli M, Gagliostro G, Auletta D, Pellegrino S, Arrigo S, Graziano F, Miele E, Illiceto MT, Alvisi P, Dilillo D, De Giacomo C, Lionetti P, Pastore M, Cananzi M, Bramuzzo M, Panceri R, Norsa L, Aloï M; SIGENP IBD Working Group. *J Pediatr Gastroenterol Nutr*. 2025 Jun;80(6):967-978. doi: 10.1002/jpn3.70029. Epub 2025 Mar 31. PMID: 40165528

SIGNIFICANT ACADEMIC EXPERIENCES

- Evidence based gastroenterology, hepatology & digestive Oncology, Torgiano (November 2012)
- Delegate at the Young Investigator Forum (YIF) 2014 of ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology and Nutrition), 24-27 September 2014, Bergen, The Netherlands
- Clinical Fellowship at the Gastroenterology Unit, Hôpital Necker-Enfants Malades, APHP, Paris Descartes University, Paris, France (January 2018 –January 2019)
- ESPGHAN Mentorship Program Brussels, Belgium (March 16 – 17 2018)
- ESPGHAN 5th Paediatric IBD Masterclass, Malaga, Spain (November 28 – 30, 2019)
- Y-ECCO 2023 Mentorship Forum, Vienna, Austria, (June 29 – 30 2023)

INVOLVEMENT IN CLINICAL TRIALS

2019 A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PURSUIT 2). Role: Co-Investigator
"Tasty&Healthy" is not a diet but a dietary approach: randomized controlled trials of excluding pro-inflammatory nutrients for inducing and maintaining remission in Crohn's disease Role: Co-Investigator
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial Role: Co-Investigator
Open-Label Induction And Maintenance Study Of Oral Cp-690,550 (Tofacitinib) In Children With Moderately To Severely Active Ulcerative Colitis. Role: Co-Investigator
Towards the path of precision medicine: new non-invasive markers for inflammatory bowel disease. Prokineticin 2, lipocalin-2, brain-derived neurotrophic factor and nerve growth factor: a pilot study Role: Principal Investigator
A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis. Role: Sub-investigator
"A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease" Protocol PLATFORMPBCRD3001/I6T-MC-PIBD, CNTO1959PBCRD3007 and I6T-MC-AMAY (MACARONI-23). Role: Sub-investigator

FOREIGN LANGUAGES

	ENGLISH	FRENCH
Reading	HIGH(C2)	HIGH (C2)
Writing	HIGH(C2)	HIGH (C2)
Conversation	HIGH(C2)	HIGH (C2)

SCIENTIFIC SOCIETIES MEMBERSHIP

ESPGHAN Member ID 1282
ECCO Member ID: 41673
SIGENP Member

In compliance with the GDPR and the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

September 1st, 2025

Giulia D'Arcangelo

